Fungal infections in solid organ transplant patients;Infecciones por hongos en el paciente sometido a trasplante de organo solido

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue SUPPL. 2, 1997, Pages 34-50

  Muñoz, Patricia ^a   Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ADULT; ASPERGILLUS; CANDIDA; CASE REPORT; FEMALE; FUNGUS; HUMAN; MALE; MUCORMYCOSIS; MYCOSIS; ORGAN TRANSPLANTATION; REVIEW; RISK ASSESSMENT; SPAIN;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CELIAC ARTERY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUCORMYCOSIS; MYCOSES; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THROMBOSIS; TIME FACTORS; TRANSPLANTATION; TRIAZOLES;

EID: 0030926574     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (241)

1. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-688.
2. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9: 1.045-1.074.
3. Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209-216.
4. Dummer JS, Bahnson HT, Griffith BP, Hardesty RL, Thomson ME, Ho M. Infections in patients on cyclosporine and prednisone following cardiac transplantation. Transplant Proc 1983; 15: 2.779-2.881.
5. Trail KC, Stratta RJ, Larsen JL, Ruby EL, Patil KD, Langnas AN et al. Results of liver transplantation in diabetic recipients. Surgery 1993; 114: 650-658.
6. Scroggs MW, Wolfe JA, Bollinger RR, Sanfilippo F. Cause of death in renal transplant recipients: a review of autopsy findings from 1966 through 1985. Arch Pathol Lab Med 1987; 111: 983-987.
7. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996; 61: 402-406.
8. Rifkind D, Marchioro T, Schneck S et al. Systemic fungal infection complicating renal transplantation and immunosuppressive therapy. Am J Med 1967; 43: 28-38.
9. Bach MC, Sahyoun A, Adler JL et al. Influence of rejection therapy on fungal and nocardial infections in renal-transplant recipients. Lancet 1973; 1: 180-184.
10. Perfect JR, Durack DT, Gallis HA. Cryptococcemia. Medicine 1983; 2: 98.
11. Najarian JS, Fryd DS, Strand M et al. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985; 201: 142-157.
12. Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis 1989; 11: 677-690.
13. Roilides E, Robinso T, Sein T, Pizzo PA, Walsh TJ. In vitro and in vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus. Antimicrob Agents Chemother 1994; 38: 2.883-2.888.
14. Levitz SM. Overview of host defences in fungal infections. Clin Infect Dis 1992; 14: S37.
15. George MJ, Snydman DR, Werner BG, Dougherty N, Griffith J, CMVIG Study group. Cytomegalovirus disease as a risk factor for fungal disease in orthotopic liver transplant recipients [resumen 32]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim: American Society for Microbiology, 1992.
16. Duncan SR, Paradis IL, Yousem SA, Similo SL, Grgurich WF, Williams PA, Dauber JH, Griffith BP. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1.419-1.425.
17. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1.019-1.054.
18. Stratta RJ, Shaefer MS, Cushing KA, Marking RS, Reed EC, Langnas AN et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992; 127: 55-64.
19. Hall KA, Copeland JG, Zukoski CF, Sethi GK, Galgiani JN. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. Transplantation 1993; 55: 1.422-1.424.
20. Hall KA, Sethi GK, Rosado LJ, Martínez JD, Huston CL, Copeland JG. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant 1993; 12: 525-526.
21. Wong SY, Allen DM. Transmission of disseminated histoplasmosis via cadaveric renal transplantation: case report. Clin Infect Dis 1992; 14: 232-234.
22. Superdock KR, Dummer JS, Koch MO, Gilliam DM, Van Buren DH, Nylander WA et al. Disseminated histoplasmosis presenting as urinary tract obstruction in a renal transplant recipient. Am J Kidney Dis 1994; 23: 600-604.
23. Gottesdiener KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med 1989; 110: 1.001.
24. Collins LA, Samore MH, Robers MS et al. Risk factors for early invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652.
25. Rubin R, Wolfson JS, Cosimi AB et al. Infection in the renal transplant patient. Am J Med 1981; 70: 405-411.
26. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart and liver transplant recipients on cyclosporin. Transplantation 1983; 36: 259-267.
27. Loire R, Tabib A, Bastien O. Fatal aspergillosis after cardiac transplantation. About 26 cases. Ann Pathol 1993; 13: 157-163.
28. Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J Heart Lung Transplant 1992; 11: 847-866.
29. Hummel M, Thalmann U, Jautzke G, Staib F, Seibold M, Hetzer R. Fungal infections following heart transplantation. Mycoses 1992; 35: 23-34.
30. Petri WA. Infections in heart transplant recipients. Clin Infect Dis 1994; 18: 141-146.
31. Muñoz P, Palomo J, Pelaez T, Muñoz R, Rodríguez-Creixems M, Bouza E. Lung nodular lesion in heart transplant recipients. 34th Interscience conference of antimicrobial agents and chemotherapy [resumen 9-J4]. Orlando: American Society for Microbiology, 1994.
32. Fisher J, Tuazon CU, Gellhoed GW. Mucormycosis in transplant patients. Am Surg 1980; 46: 315-322.
33. Hall JC, Brewer JH, Reed WA, Steinhaus DM, Watson KR. Cutaneous mucormycosis in a heart transplant patient. Cutis 1988; 42: 183-186.
34. Studemeiste AE, Kozak K, Garrity E, Venezio E, Venezio FR. Survival of a heart transplant recipient after pulmonary cavitary mucormycosis. J Heart Transplant 1988; 7: 159-161.
35. Mancini MC, McGinnis MR. Dactylaria infection of a human being: pulmonary disease in a heart transplant recipient. J Heart Lung Transplant 1992; 11: 827.
36. Sudduth EJ, Crumbley AJ, Farrar WE. Phaeohyphomycosis due to Exophiala species. Clinical spectrum of disease in humans. Clin Infect Dis 1992; 15: 639.
37. Dummer JS, Montero CG, Griffith BP, Hardestry RL, Paradis IL, Ho M. Infections in heart-lung transplant recipients. Transplantation 1987; 41: 725-729.
38. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant recipients. Am J Med 1985; 79: 412-422.
39. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11: 291-308.
40. Kramer MR, Marshall SE, Denning DW et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327.
41. Kramer MR, Marshall SE, Starnes VA et al. Infectious complications in heart-lung transplantation. Arch Intern Med 1993; 153: 2.010-2.016.
42. Patel SR, Kirby TJ, McCarthy PM, Meeker DP, Stillwell P, Rice TW et al. Lung Transplantation: the Cleveland Clinic experience. Cleve Clin J Med 1993; 60: 303-319.
43. Dowling RD, Baladi N, Zenati M et al. Disruption of the aortic anastomosis after heart-lung transplantation. Ann thorac Surg 1990; 49: 118-122.
44. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991; 144: 552-556.
45. Gavaldà J, Román A, Bravo C et al. Profilaxis con amfotericina B nebulizada y ganciclovir en pacientes con trasplante pulmonar [resumen 133]. VI Reunión de la SEIMC, Valencia, 1994.
46. Kusne S, Dummer JS, Singh N et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67: 132-143.
47. Wajszczuk CP, Dummer JS, Ho M et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-353.
48. Castaldo P, Stratta RJ, Wood RP et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-156.
49. Benedict LM, Kusne S, Torre-Cisneros J, Hunt SJ. Primary cutaneous fungal infection after solid-organ transplantation: report of five cases and review. Clin Infect Dis 1992; 15: 17-21.
50. Hadley S, Samore MH, Lewis DW et al. Major infectious complicating after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1955; 59: 851.
51. Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-588.
52. Romanyk J, Del Palacio A, Fiaño C, Lumbreras C, Cuetara S, Moreno P et al. Micosis invasoras en trasplantados hepáticos. Enferm Infecc Microbiol Clin 1991; 9: 323-328 [Fe de errores en Enferm Infecc Microbiol Clin 1991; 9: 454].
53. Tollemar J, Ericzon EB, Barkholt L, Anderson J, Ringden O, Groth CG. Risk factors for deep Candida infections in liver recipients. Transplant Proc 1990; 22: 1.826-1.827.
54. Mora NP, Klintmalm G, Solomon H, Goldstein RM, Gonwa TA, Husberg BS. Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant. Transplant Proc 1992; 24: 154-155.
55. Saint-Vil D, Luks FL, Lebel P, Brandt ML, Paradis K, Weber A et al. Infectious complications of pediatric liver transplantation. J Pediatr Surg 1991; 26: 908-913.
56. Moreno A, Mensa J, Almela M et al. Estudio de 138 episodios de bacteriemia o funguemia en pacientes con trasplante de órgano sólido (renal o hepático). Med Clin (Barc) 1994; 103: 161-164.
57. Potter van Loon BJ, Lichtendahl AT, Mulder SS, Van Houten H, Gooszen HG, Van den Broek PJ. Microbial contamination of donor duodenum in whole-pancreas transplantation. Diabetes 1989; 38: 242-243.
58. Boon AP, O'Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991; 44: 452-454.
59. Rossi G, Tortorano AM, Viviani MA et al. Aspergillus fumigatus infections in liver transplant patients. Transplant Proc 1989; 21: 2.268.
60. Pla MP, Berenguer J, Arzuaga JA, Bañares R, Polo JR, Bouza E. Surgical wound infection by Aspergillus fumigatus in liver transplant recipients. Diag Microbiol Infect Dis 1992; 15: 703-706.
61. Welty FK, McLeod GX, Ezratty C, Healy RW, Karchmer AW. Pseudallescherichia boydii endocarditis of the pulmonic valve in a liver transplant recipient. Clin Infect Dis 1992; 15: 858-860.
62. Colonna JO, Winston DJ, Brill JE et al. Infectious complications in liver transplantation. Arch Surg 1988; 123: 360-364.
63. Baliga P, Merion RM, Turcotte JG, Ham JM, Henley KS, Lucey MR et al. Preoperative risk factor assessment in liver transplantation. Surgery 1992; 112: 704-710.
64. Brems JJ, Hiatt JR, Klein AS et al. Disseminated aspergillosis complicating orthotopic liver transplantation for fulminant hepatic failure refractory to corticosteroid therapy. Transplantation 1988; 46: 479-481.
65. Castaldo P, Stratta RJ, Wood RP et al. Fungal disease in liver transplant recipients: a multivariate of risk factors. Transplant Proc 1991; 23: 1.517-1.519.
66. Kusne S, Torre-Cisneros J, Mañez R et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1.379-1.383.
67. Lumbreras C, Fernández I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995; 20: 514-520.
68. Sollinger HW, Knechtle SJ, Reed A et al. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. Ann Surg 1991; 214: 703-711.
69. Abendroth D, La Greca G, Capalbo M et al. Infections in simultaneous pancreas transplantation duct. Occlusion vs bladder drainage. Transplant Proc 1992; 24: 297.
70. Perkins JD, Frohnert PP, Service FJ et al. Pancreas transplantation at Mayo III. Multidisciplinary management. Mayo Clin Proc 1990; 65: 496-508.
71. Howard RJ, Simmons RL, Najarian FS. Fungal infections in renal transplant recipients. Ann Surg 1978; 187: 126-133.
72. Peterson PK, Balfour HH, Fryd DS et al. Fever in renal transplant recipients: causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med 1981; 71: 345-351.
73. King D, Pasarell L, Dixon DM, McGinnis MR, Merz WG. A phaeohyphomycotic cyst and peritonitis caused by Phialemonium species and a reevaluation of its taxonomy. J Clin Microbiol 1993; 31: 1.804-1.810.
74. Wise KA, Speed BR, Ellis DH, Andrew JH. Two fatal infections in immunocompromised patients caused by Scedosporium inflatum. Pathology 1993; 25: 187-189.
75. Cohen J, Hopkin J, Kurtz J. Infectious complications after renal transplantation. En: Morris PJ, ed. Kidney Transplantation. Principles and Practice. Filadelfia: WB Saunders, 1988; 533.
76. Gallis HA, Bernam RA, Cate TR et al. Fungal infections following renal transplantation. Arch Intern Med 1975; 135: 1.163.
77. Peterson PK, Ferguson R, Fryd DS et al. Infectious diseases in hospitalized renal transplant recipients. A prospective study of a complex and evolving problem. Medicine 1982; 59: 283.
78. Anandi V, John TJ, Walter A et al. Cerebral phaeohyphomycosis caused by Chaetomium globosum in a renal transplant recipient. J Clin Microbiol 1989; 27: 2.226.
79. Hamida MB, Achard JM, Sesteel PF et al. Leg granuloma due to Neocosmospora vasinfecta in a renal graft recipient. Transplant Proc 1993; 25: 2.292.
80. Hamida MB, Bedrossian J, Pruna A et al. Fungal mycotic aneurysms and visceral infection due to Scedosporium apiospermum in a kidney transplant patient. Transplant Proc 1993; 25: 2.290.
81. Hsu J, Clayman JA, Geha AS. Survival of a recipient of renal transplantation after pulmonary phycomycosis. Ann Thorac Surg 1989; 47: 617.
82. Nordén G, Björck S, Persson H et al. Cure of zygomycosis caused by a lipase-producing Rhizopus rhizopodiformis strain in a renal transplant patient. Scand J Infect Dis 1991; 23: 377.
83. Walker SD, Clark RV, King CT et al. Fatal disseminated Conidiobolus coronatus infection in a renal transplant patient. Am J Clin Pathol 1992; 98: 559.
84. Cohen IM, Galgiani JN, Potter D et al. Coccidiomycosis in renal placement therapy. Arch Intern Med 1982; 142: 489.
85. Wheat JL, Smith EJ, Sathapatayavongs B et al. Histoplasmosis in renal allograft recipients. Two large urban outbreaks. Arch Intern Med 1983; 143: 703.
86. Fisher JF, Chew WH, Shadomy S et al. Urinary tract infections due to Candida albicans. Rev Infect Dis 1982; 4: 1.107.
87. Chugh KS, Sakhuja V, Jain S et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dial Transplant 1993; 8: 163.
88. Weiland D, Ferguson RM, Peterson PK et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis and management. Ann Surg 1983; 198: 622-629.
89. Gustafson TL, Schaffner W, Lavely GB et al. Invasive aspergillosis in renal transplant recipients. Correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230.
90. Rubin RH. Fungal and bacterial infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 1993; 12: 42-48.
91. Wakefield AE, Peters SE, Banerji S, Bridge PD, Hall GS, Hawksworth DL et al. Pneumocystis carinii shows DNA homology with the ustomycetous red yeast fungi. Mol Microbiol 1992; 6: 1.903-1.911.
92. Serody JS, Mill MR, Detterbeck FC et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993; 16: 54.
93. Ringdén O, Tollemar J, Tyden G. High cure rate of invasive fungal infections in immunocompromised children using ambisome. Transplant Proc 1994; 26: 175.
94. Simsek U, Akinci H, Oktay B, Kavrama I, Ozyurt M. Treatment of catheter-associated candiduria with fluconazole irrigation. Br J Urol 1995; 75: 75-77.
95. Wey SB, Motomi M, Pfaller MA et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2.349.
96. Nguyen MH, Peacock JE, Tanner DC et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995; 155: 2.429-2.435.
97. Lecciones JA, Lee JS, Navarro EE et al. Vascular catheter-associated fungemia in patients with cancer. Analysis of 155 episodes. Clin Infect Dis 1992; 14: 875.
98. Obias AA, Boschman CR, Noskin GA et al. Surveillance of in-patient transplant and oncology patients for resistance to antifungal agents in yeast isolates [resumen E050]. 36th ICAAC Conference, 1996.
99. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Arch Intern Med 1971; 128: 541-545.
100. Linder J. Infection as a complication of heart transplantation. J Heart Transplant 1988; 7: 390-394.
101. Britt RH, Enzmann DR, Remington JS. Intracranial infection in cardiac transplant recipients. Ann Neurol 1981; 19: 107-119.
102. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airbone disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982; 116: 430-437.
103. Arnow PM, Andersen RL, Mainous PD, Smith EJ. Pulmonary aspergillosis during hospital renovation. Am Rev Resp Dis 1978; 118: 49-53.
104. Muñoz P. Torre J, Bouza E, Moreno A, Echaniz A, Fortún J, and the Spanish Group for Infections in Transplant patients (GESITRA). A large Multicentric Study. Invasive Aspergillosis (IA) in Transplant Recipients. New Orleans: 36 ICAAC Meeting, 1996 [resumen J128].
105. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8: 413-437.
106. Gentry LO, Zeluff BJ. Diagnosis and treatment of infection in cardiac transplant. Surg Clin North Am 1986; 66: 459-465.
107. Denning DW. Treatment of invasive aspergillosis. J Infect 1994; 28: 25-33.
108. Meyer JM, Nimer L, Carroll K. Isolated pulmonary aspergillar infection in cardiac transplant recipients: case report and review. Clin Infect Dis 1992; 15: 698-700.
109. Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1.044-1.050.
110. Moreau P, Zahar JR, Milpied N et al. Localizated invasive aspergillosis in patients with neutropenia. Effectiveness of surgical resection. Cancer 1993; 72: 3.223-3.226.
111. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1.147-1.201.
112. Hummel M, Schuler S, Weber U et al. Aspergillosis with Aspergillus osteomyelitis and diskitis after heart transplantation: surgical and medical management. J Heart Lung Transplant 1993; 12: 599-603.
113. Sugar AM. Mucormycosis. Clin Infect Dis 1992; 14: 126-129.
114. Berenguer J, Solera J, Moreno S, Muñoz P, Parras F, Bouza E. Mucormicosis: el espectro de la enfermedad en 13 pacientes. Med Clin (Barc) 1990; 94: 766-772.
115. Morduchowicz G, Shmueli D, Shapira Z et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis 1986; 8: 441.
116. Munckhof W, Jones R, Tosolini FA et al. Cure of rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B. Clin Infect Dis 1993; 16: 183.
117. Singh N, Gayowski T, Singh J, Yu LV. Invasive gastrointestinal zygomycosis in a liver transplant recipient and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 1995; 20: 617-620.
118. Baraia J, Muñoz P, Bernaldo de Quirós JC, Bouza E. Cutaneous mucormycosis in a heart transplant patients associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis 1995; 14: 813-815.
119. Fortún J, Palomo J, Muñoz P, Carretero L. Infiltrados pulmonares e insuficiencia respiratoria en un trasplantado cardiaco con primoinfección por citomegalovirus. Rev Clin Esp 1995; 195: 649-670.
120. Keys TF, Rhodes KH. Nosocomial outbreak of Rhizopus infections associated with Elastoplast wound dressings. MMWR 1978; 27: 33-34.
121. Paparello SF, Parry RL, MacGillivray DC, Brock N, Mayers DL. Hospital acquired wound mucormycosis. Clin Infect Dis 1992; 14: 350-352.
122. Adam RD, Hunter G, DiTomasso J, Comerci G. Mucormycosis: emerging prominence of cutanoeus infections. Clin Infect Dis 1994; 19: 67-76.
123. Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR, Risk Factors for Invasive Fungal Infections in Liver Transplant Recipients Receiving Tarolimus (FK506) as Primary Immunosuppression [póster J125]. 35th ICAAC meeting. Nueva Orleans, 1996.
124. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993; 17:S487-S491.
125. Anaissie EJ, Bodey GP, Rinaldi MG. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis 1989; 8: 323-330.
126. Repiso T, Martin N, Huguet P et al. Cutaneous alternariosis in a liver transplant recipient. Clin Infect Dis 1993; 16: 729-730.
127. Rinaldi MG, Phillips P, Schwarz JG et al. Human Curvularia infections. Report of five cases and review of the literature. Diag Microbiol Infect Dis 1987; 6: 27-39.
128. Adam RD, Paquín ML, Petersen EA et al. Phaeohyphomycosis caused by the fungal genera Bipolaris an Exserohilum. A report of 9 cases and review of the literature. Medicine (Baltimore). 1986; 65: 203-217.
129. Wiest PM, Wiese K, Jacobs MR, Morisey AB, Abelson TI, Witt et al. Alternaria infection in a patient with Acquired Immunodeficiency Syndrome: a case report and review of invasive Alternaria infections. Rev Infect Dis 1987; 9: 799-803.
130. Aldape KD, Fox HS, Roberts JP, Ascher NL, Lake JR, Rowley HA. Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipients. Report of a case. Am J Clin Pathol 1991; 95: 499-502.
131. Singh N, Bonham A, Dominguez EA, Fukui M, Pankey GA, Paterson D et al. Central Nervous System (CNS) Lesions in Liver Transplant Recipients: Prospective Assessment of Indications for Biopsy and Implications for Management [póster J127]. 35th ICAAC meeting. Nueva Orleans, 1996.
132. Hachisuka H, Matsumoto T, Kusuhara M, Nomura H, Nakano S, Sasai Y. Cutaneous pheohyphomycosis caused by Exophiala jcanselmei after renal transplantation. Int J Dermatol 1990; 29: 198-200.
133. Anandi V, John TJ, Walter A, Shastry JC, Lalitha MK, Padhye AA et al. Cerebral phaeohyhomycosis caused by Chaetomium globosum in a renal transplant recipient J Clin Microbiol 1989; 27: 2.226-2.229.
134. Bouza E, Muñoz P, Vega L, Rodríguez-Créixems M, Berenguer J, Escudero A. Clinical resolution of Seedosporium profilicans fungemia associated with reversal of neutropenia following administration of granulocyte coloni-stimulating factor. Clin Infect Dis 1996; 23: 192-193.
135. Berenguer J, Diaz Mediavilla J, Urra D, Muñoz P. Central nervous system infection caused by Pseudoallescheria boydii. Case report and review. Rev Infect Dis 1989; 6: 890-895.
136. Jacobs F, Byl B, Bourgeois N et al. Trichoderma viridae infection in a liver transplant recipient. Mycoses 1992; 33: 501.
137. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore). 1988; 67: 77-83.
138. Aucott JN, Fayen J, Grossnicklas H, Morrissey A, Lederman MM, Salata RA. Invasive infection with Saccharomyces cerevisiae: a report of three cases and review. Rev Infect Dis 1990; 12: 406-411.
139. Muñoz P, García Leoni ME, Berenguer J, Bernaldo de Quirós JC, Bouza E. Catheter-related fungemia by Hansenula anomala. Arch Intern Med 1989; 149: 709-713.
140. Mirza SH. Disseminated Trichosporon beigelii infection causing skin lesions in a renal transplant recipient. J Infect 1993; 26: 67.
141. Walsh TJ. Trichosporonosis. Infect Dis Clin North Amer 1989; 3: 43-52.
142. Klotz SA. Malassezia furfur. Infect Dis Clin North Am. 1989; 3: 53-64.
143. Tang CV, Cohen J. Diagnosing fungal infections in immunocompromised hosts. Clin Pathol 1992; 45: 1.
144. Muñoz P, Bernaldo de Quirós JCL, Berenguer J, Rodríguez Créixems M, Picazzo JJ, Bouza E. The impact of the Bactee NR system in the diagnosis of Candida funguemia. J Clin Microbiol 1990; 28: 639-641.
145. Lyon R, Woods G. Comparison of the BacT/alert and Isolator blood culture systems for recovery of fungi. Am J Clin Pathol 1995; 103: 660-662.
146. Tollemar J, Ericzon BG, Homber K et al. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc 1990; 22: 242.
147. Sandford GR, Merz WG, Wingard JR et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142: 503.
148. Kahn FW, Jones JM, England DM. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol 1986; 86: 518.
149. Nalesnick MA, Nyerowitz RL, Jenkins R et al. Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 1980; 11: 370.
150. Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in the diagnosis of invasive pulmonary aspergillosis.Am J Med 1986; 81: 249.
151. Cazzadori A, Di Perri G, Todeschini G et al. Transbronchial biopsy in the diagnosis of pulmonary infiltrates in immunocompromised patients. Chest 1995; 107: 101-106.
152. Tolkoff-Rubin NE, Conti DJ, Doran M, DelVecchio A, Rubin RH. Fluconazole in the treatment of invasive candidal and cryptococcal infections in organ transplant recipients. Pharmacotherapy 1990; 10: 6: 159-163.
153. Snow RM, Dismukes WE. Cryptococcal meningitis. Diagnostic value of cryptococcal antigen in cerebrospinal fluid. Arch Intern Med 1975; 135: 1.155.
154. Walsh T, Merz WG, Lee JW et al. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzimatic detection of serum D-arabinitol. Am J Med 1995; 99: 164-172.
155. Terrell CL, Hughes CE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1992; 67: 69-91.
156. Lyman CA, Walsh TJ. Systematically administered agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992; 44: 9-35.
157. Francis P, Walsh TJ. Current approaches to the management of fungal infections in cancer patients: Part 1. Oncology (Williston Park) 1992; 6: 81-92.
158. Graybill JR. Future directions of antifungal chemotherapy. Clin Infect Dis 1992; 14: 170-181.
159. Muñoz P, Bouza E. Micosis sistémicas oportunistas. Aportaciones recientes. Monografia En: Comentarios a la literatura en enfermedades infecciosas. VIII. Madrid: Elba, 1994; 1-68.
160. Rubin RH, Tolkoff-Rubin EN. Antimicrobial strategies in the care of organ trasplant recipients. Antimicrob Agents Chemother 1993; 37: 619.
161. Warnock DW. Fungal complications of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother 1995; 36: 73-90.
162. Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis 1992; 14: 154-160.
163. Fisher BD, Armstrong D, Yu B, Gold JWM. Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med 1981; 71: 571-577.
164. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5: 1.985-1.993.
165. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983; 35: 211-215.
166. Burton JR, Zachery JB, Bessin R et al. Aspergillosis in four renal transplant recipients. Diagnosis and effective treatment with amphotericin B. Ann Intern Med 1972; 77: 383-388.
167. Camarata PJ, Dunn DL, Farney AC, Parker RG, Seljeskog EL. Continual intracavitary administration of amphotericin as an adjunct in the treatment of aspergillus brain abscess: cases report and review of the literature. Neurosurgery 1992; 31: 575-579.
168. Goodwing SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-761.
169. Bowler WA, Weiss PJ, Hill HE, Hoffmeister KA, Fleck RP, Blacky AR et al. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients B in patients with preserved renal function. Antimicrob Agents Chemother 1992; 36: 2.542-2.543.
170. Cruz J, Paecock JE, Loomer L et al. Rapid intravenous infusion of amphotericin B. A pilot study. Am J Med 1992; 93: 123-130.
171. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug safety 1990; 5: 94.
172. Brouhard BH, Baetz-Greenwalt B. Calcium-channel blocking agents as therapy for amphotericin B nephrotoxicity. Cleve Clin J Med 1992; 59: 263-264.
173. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2.389.
174. Gradner ML, Godley PJ, Wasan SM. Sodium loading treatment for amphotericin B-induced nephrotoxicity. Ann Pharmacother 1990; 244: 940.
175. Bianco JA, Almgren J, Kern DL et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991; 51: 925.
176. Epstein M. Calcium antagonists and the kidney: future therapeutic perspectives. Am J Kid Dis 1993; 21: 16.
177. Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis 1989; 11: 677-690.
178. Conti DJ, Tolkoff-Rubin NE, Baker GP Jr et al. Succesful treatment of invasive fungal infection with fluconazol in organ transplant recipients. Transplantation 1989; 48: 692-695.
179. Ralph ED, Barber KR, Grant CW. Clinical experience with multilamellar liposomal amphotericin B in patients with proven and sucepted fungal infections. Scand J Infect Dis 1993; 25: 487-496.
180. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis 1993; 17: 501.
181. Moreau P, Milipied N, Fayette N et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992; 30: 535.
182. Schoffski P, Wunder R, Petersen D et al. Amphotericin B in Intralipid: no evidence of improved toxicity profile. Results of a randomized phase II-trial in neutropenic patients [resumen L036]. 36th ICAAC Conference, 1996.
183. López-Berestein G, Bodey GP, Fainstein V et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2.533-2.536.
184. Katz NM, Pierce PF, Anzeck RA et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant recipient. J Heart Transplant 1990; 9: 14-17.
185. Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in the immunocompromised patients. J Antimicrob Chemother 1991; 28 (Supl B): 73-82.
186. Tollemar J, Duraj F, Ericzon BG. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses 1990; 33: 251-252.
187. Ralph ED, Barber KR, Grant CWM. Liposomal amphotericin B: an effective, nontoxic preparation for the treatment urinary tract infections caused by Candida albicans. Am J Nephrol 1991; 11: 118-122.
188. Ng TTC, Denning DW. Liposomal amphotericin B (Ambisome) therapy in invasive fungal infections. Arch Intern Med 1995; 155: 1.093-1.098.
189. Berenguer J, Muñoz P, Parras F, Fernández Baca V, Hernández Sampelayo T, Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Europ J Clin Microbiol Infect Dis 1994; 13: 504-507.
190. Ellis M, Spence D, Meunier F et al. Randomized multicentre trial of 1 mg/kg versus 4 mg/kg liposomal amphotericin B in the treatment of invasive aspergillosis. EORTC protocol 19923 [resumen L039]. 36th ICAAC Conference, 1996.
191. Ringden O, Andström E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B in 187 transplant recipients treated with cyclosporin. Symposium on Advances in the management of invasive fungal infections. Harrogate, 1994.
192. Lister J. Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy [póster 1209]. 36th annual meeting of the American Society of Hematology. Tennessee, 1994.
193. Oravcová E, Mistrik M, Sakalová A et al. Amphotericin B Lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy 1995; 41: 473-476.
194. Jones RS, Barman A, Suh B, Heifets M, Bacobo FC. Successful treatment of aspergillus vertebral osteomyelitis with amphotericin B lipid complex. Infect Dis Clin Pract 1995; 4: 237-239.
195. Walsh T, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [póster M69]. 34th ICAAC meeting. San Francisco, 1995.
196. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive infections after marrow transplant. J Infect Dis 1996; 173: 1.208-1.215.
197. Noskin GA, Coffey G, Gurwith M. Treatment of candidemia with amphotericin B colloidal dispersion. 34th IDSA Annual Meeting, 1996.
198. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317: 334-341.
199. White DJG, Blatchford NR, Cauwenbergh G. Cyclosporine and ketoconazole. Transplantation 1984; 37: 214-215.
200. Ferguson RM, Sutherland DER, Simmons RL, Najarian JS. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 1982; 2: 882-883.
201. Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889-892.
202. Rex JH, Bennet JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1.325-1.330.
203. Nolla-Salas J, Leon C, Torres JM et al. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992; 14: 952.
204. Bren A, Kandus A, Lindic J, Varl J. Fluconazole in the treatment of fungal infections in kidney-transplanted patients. Transplant Proc 1992; 24: 2.765-2.766.
205. Agarwal A, Gupta A, Sakhuja V, Talwar P, Joshi K, Chugh KS, Retinitis following disseminated cryptococcosis in a renal allograft recipient. Efficacy of oral fluconazole. Acta Ophthalmol (Copenh) 1991; 69: 402-405.
206. Lye WC, Chin NK, Lee YS. Disseminated cryptococcosis presenting with a pleural effusion in a kidney transplant recipient: early diagnosis by pleural biopsy and succesful treatment with oral fluconazole. Nephron 1993; 65: 646.
207. Hibberd PL, Tolkoff-Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994; 19: 33.
208. Muñoz P, Moreno S, Berenguer J, Bernaldo de Quirós JCL, Bouza E. Fluconazole related hepatotoxicity. Arch Intern Med 1991; 151: 1.020-1.021.
209. Sugar AM, Saunders C, Idelson BA, Bernard DB. Interaction of fluconazole and cyclosporine. Ann Intern Med 1989; 110: 844.
210. Kruger HU, Schuler U, Zimmerman R, Ehninger G. No severe drug interaction of fluconazole, a triazole antifungal agent, with cyclosporine. Bone Marrow Transplant 1988; 324-325.
211. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12: 327-333.
212. Horton CM, Freeman CD, Nolan PE Jr, Copeland JG. Cyclosporine interactions with miconazole and other azole-antimycotics: a case report and review of the literature. J Heart Lung Transplant 1992; 11: 1.127-1.132.
213. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1.014-1.018.
214. Barbara JA, Clarkson AR, LaBrooy J, McNeil JD, Woodroffe AJ. Candida albicans arthritis in a renal allograft recipient with an interaction between cyclosporin and fluconazole. Nephrology, dialysis, transplantation 1993; 8: 263-266.
215. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabet Metabolism 1994; 20: 49-52.
216. Le Conte P, Joly V, Saint-Julien L, Gillardin JM, Carbon C, Yeni P. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Respir Dis 1992; 145: 424-429.
217. Blandloeil Y, Francois T, Germaud P et al. Invasive aspergillosis in surgical intensive care patients. Ann Fr Anesth Reanim 1993; 12: 379-384.
218. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791-800.
219. Viviani MA, Tortorano AM, Woestenborghs R, Cauwenbergh G. Experience with itraconazole in deep mycoses in northern Italy. Mykosen 1987; 30: 233-244.
220. Jennings TS, Hardin TC. Treatment of aspergillosis with itraconazole. Ann Pharmacother 1993; 27: 1.206-1.211.
221. Masclans JR, Pérez A, Tenorio L, Planas M. The use of itraconazole in liver transplantation. Med Clin (Barc) 1992; 99: 477.
222. Gamba A, Fiocchi R, Ferrazzi P et al. Pulmonary and disseminated aspergillosis in cardiac transplanted patients: itraconazole as a first choice therapy? J Heart Transplant 1991; 10: 189.
223. Faggian G, Bortolotti U, Mazzuco A et al. Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc 1989; 21: 2.506-2.507.
224. McDougall JC, Vigneswaran WT, Peters SG, Marshall WT, McGregor CG. Fungal infection of the contralateral native lung after single-lung transplantation. Ann Thorac Surg 1993; 56: 176-178.
225. De Buele K, De Doncker P, Cauwenbergh G et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of a open international study (1982-1987). Mycoses 1988; 31: 476-485.
226. Denning DW. Diagnosis and management of invasive aspergillosis. Current Clinical Topics in Infect Dis 1996; 277-299.
227. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
228. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole. Lancet 1987; 2: 282.
229. Zuckerman JM, Tunkel AR. Itraconazole. A new triazole antifungal agent. Infect Control Hosp Epidemiol 1994; 15: 397.
230. Bouffard FA, Dropinski JF, Balkovec JM et al. L-743,872, a novel antifungal lipopeptide: synthesis and structure activity relationship of new aza-substituted pneumocandins [resumen F027]. 36th ICAAC Conference, 1996.
231. Nelson PW, Lozano M, Rex JH. In vitro activity of L-743,872 against putatively amphotericin B and fluconazole-resistant Candida isolates [resumen F028]. 36th ICAAC Conference, 1996.
232. Espinelingroff A, Flynn T. Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens: a comparative study [resumen F083]. 36th ICAAC Conference, 1996.
233. Espinelingroff A. Antifungal activity of the in vitro activity of the new triazole voriconazole against opportunistic filamentous fungi. [resumen F084]. 36 th ICAAC Conference, 1996.
234. Maesaki S, Kohno S, Kaku M, Koga H, Hara K. Effects on antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother 1994; 38: 2.843-2.845.
235. Polak A. Combination therapy in systemic mycosis. J Chemother 1990; 2: 221.
236. Ramani A, Louie A, Ramani R, Drusano GL, Taber H, Sheyagani M. Are polyene and azole antifungal combinations antagonistic in vitro? [resumen E046]. 36th ICAAC Conference, 1996.
237. Fothergill AW, Leitber I, Meingassner JG, Ryder NS, Rinaldi MG. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazol [resumen E053]. 36th ICAAC Conference, 1996.
238. Sugar AM. Use of amphotericin B with azole antifungal drus: what are we doing? Antimicrob Agents Chemother 1995; 39 :1.907-1.912.
239. Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant patients. Lancet 1984; 1: 1.989-1.990.
240. Neumanitis J, Meyers JD, Buckner CD et al. Phase: I trial of recombinant human macrophage colony-stimulating factor in patients with invasive infections. Blood 1991; 78: 907-913.
241. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol 1991; 13: 400-413.